WaltersCL,ArendRC,ArmstrongDK,etal.FolateandfolatereceptoralphaantagoNISTsmechanismofactioninovariancancer.GynecolOncol.2013Nov;131(2):493-8.PMID:23863359.
LauDH,MoonJ,DaviesAM,etal.SouthwesternoncologygroupphaseIItrial(S0526)ofpemetrexedinbronchioloalveolarcarcinomasubtypesofadvancedadenocarcinoma.ClinLungCancer.2013Jul;14(4):351-5.PMID:23415808.
YangTY,ChangGC,ChenKC,etal.Pemetrexedinducesbothintrinsicandextrinsicapoptosisthroughataxiatelangiectasiamutated/p53-dependentand-independentsignalingpathways.MolCarcinog.2013Mar;52(3):183-94.PMID:22086658.
SuL,LiuG,HaoX,etal.Deathreceptor5andcellularFLICE-inhibitoryproteinregulatepemetrexed-inducedapoptosisinhumanlungcancercells.EurJCancer.2011Nov;47(16):2471-8.PMID:21726997.
DaidoneF,FlorioR,RinaldoS,etal.Insilicoandinvitrovalidationofserinehydroxymethyltransferaseasachemotherapeutictargetoftheantifolatedrugpemetrexed.EurJMedChem.2011May;46(5):1616-21.PMID:21371789.
JoergerM,OmlinA,CernyT,etal.Theroleofpemetrexedinadvancednonsmall-celllungcancer:specialfocusonpharmacologyandmechanismofaction.CurrDrugTargets.2010Jan;11(1):37-47.PMID:19839929.
BlackwoodE,EplerJ,YenI,etal.Combinationdrugschedulingdefinesa“windowofopportunity”forchemopotentiationofgemcitABInebyanorallybioavailable,selectiveChK1inhibitor,GNE-900.MolCancerTher.2013Oct;12(10):1968-1980.PMID:23873850.